Common use of Euros Clause in Contracts

Euros. €) per subject to be evaluated, as established by the Financial Schedule attached as SCHEDULE 1 to this Agreement, which specifies all economic aspects. This amount does not cover or provide for any obligation or commitment for the HOSPITAL, the FOUNDATION and/or the PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, purchase, use, or agree to the use of any of the SPONSOR’s products. The sum to be paid by the SPONSOR/CRO during the implementation of the CLINICAL TRIAL shall be set according to the specifications of SCHEDULE 1, and shall be paid to the FOUNDATION as detailed below: €2,000 to be paid by Administrative Management of the present contract according to the established in the STUDY BUDGET (APPENDIX 1); The remainder of the CLINICAL TRIAL budget shall be paid, at least each semester, as detailed in the table of cost per visit and recruited patient included as APPENDIX 1 until the total cost of the budget is fully paid. The SPONSOR and the PRINCIPAL INVESTIGATOR shall report to the FOUNDATION trimestrally; These instalments shall be considered as partial payments, subject to the settlement of the final total expenses of the CLINICAL TRIAL. The final contribution of the SPONSOR for the implementation of the CLINICAL TRIAL shall be determined by the activities actually performed while conducting the CLINICAL TRIAL (“Finalcost”). Final cost shall be estimated as follows: Within a maximum of three (3) months from completion of the TRIAL at the HOSPITAL, the SPONSOR/CRO and the PRINCIPALINVESTIGATOR shall report in writing to the FOUNDATION the total number of (1) recruited and evaluated subjects, (2) actual number of visits, (3) resulting incidents, as well as (4) any tests, analyses, examinations, consultations, or hospital stays of special nature that might have occurred, whether or not included in the Financial Schedule (APPENDIX 1); As soon as possible after the information of the previous point has been reported, the FOUNDATION shall calculate and notify the SPONSOR/CROof the final payment of the CLINICAL TRIAL, as well as the outstanding sums, if any, which shall be paid within one (1) month without further requirement. This settlement of the final payment shall be regarded to all effects as due compliance by the SPONSOR of his financial obligations. All payments shall be made upon the presentation of an invoice; the corresponding VAT shall be included as per current legislation at the time of payment, inthe name of theSPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details). ENTITY IN CHARGE OF FINANCIAL ASPECTS (Invoicing Details) NAME VAT NUMBER/ TAX ID NUMBER REGISTERED ADDRESS

Euros. €) per subject to be evaluated, as established by the Financial Schedule attached as SCHEDULE 1 to this Agreement, ,which specifies all economic aspects. This amount does not cover or provide for any obligation or commitment for the HOSPITAL, the FOUNDATION and/or the PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, purchase, use, or agree to the use of any of the SPONSOR’s products. The sum to be paid by the SPONSOR/CRO during the implementation of the CLINICAL TRIAL shall be set according to the specifications of SCHEDULE 1, and shall be paid to the FOUNDATION as detailed below: €2,000 to be paid by Administrative Management of the present contract according to the established thatestablished in the STUDY BUDGET (APPENDIX SCHEDULE 1); The remainder of the CLINICAL TRIAL budget shall be paid, at least each semester, as detailed in the table of cost per visit and recruited patient included as APPENDIX 1 inSCHEDULE 1, until the total cost of the budget is fully paid. The SPONSOR and the PRINCIPAL INVESTIGATOR shall report to the FOUNDATION trimestrally; FOUNDATIONtrimestrally. These instalments shall be considered as partial payments, subject to the settlement of the final total expenses of the CLINICAL theCLINICAL TRIAL. The final contribution of the SPONSOR for the implementation of the CLINICAL TRIAL shall be determined by the activities actually performed while conducting the CLINICAL TRIAL (“Finalcost”). Final cost shall be estimated as follows: Within a maximum of three (3) months from completion of the TRIAL at the HOSPITAL, the SPONSOR/CRO and the PRINCIPALINVESTIGATOR shall report in writing to the FOUNDATION the total number of (1) recruited and evaluated subjects, (2) actual number of visits, (3) resulting incidents, as well as (4) any tests, analyses, examinations, consultations, consultations or hospital stays of special nature that might have occurred, whether or not included in the Financial Schedule (APPENDIX SCHEDULE 1); As soon as possible after the information of the previous point has been reported, the FOUNDATION shall calculate and notify the SPONSOR/CROof the final payment of the CLINICAL TRIAL, as well as the outstanding sums, if any, which shall be paid within one (1) month without further requirement. This settlement of the final payment shall be regarded to all effects as due compliance by the SPONSOR of his financial obligations. All payments shall be made upon the presentation of an invoice; the corresponding VAT shall be included as per current legislation at the time of payment, inthe name of theSPONSOR the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details). ENTITY IN CHARGE OF FINANCIAL ASPECTS (Invoicing Details) NAME VAT NUMBER/ TAX ID NUMBER REGISTERED ADDRESSADDRESS All payments to the Foundation shall be by bank transfer (with bank fees being paid by the payer) to: Beneficiary:La Paz University Hospital Foundation for Biomedical Research CIF/VAT Number/ TAX ID Number: G 00000000 Banking Entity: La Caixa, C/ Hermanos Xxxxxx Xxxxxxxx 18 (Madrid) Account Number:2100 4065 13 2200092143 IBAN: XX00 0000 0000 0000 0000 2143 SWIFT: CAIXE SBB Payments by the SPONSOR/CRO to the FOUNDATION shall be in full satisfaction by the former of its obligations, it being the FOUNDATION’s responsibility to pay the sums, if any, due to the researchers and/or the subjects of the trial.

Euros. €) per subject to be evaluated, as established by the Financial Schedule attached as SCHEDULE 1 to this Agreement, ,which specifies all economic aspects. This amount does not cover or provide for any obligation or commitment for the HOSPITAL, the FOUNDATION and/or the PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, purchase, use, or agree to the use of any of the SPONSOR’s products. The sum to be paid by the SPONSOR/CRO during the implementation of the CLINICAL TRIAL shall be set according to the specifications of SCHEDULE 1, and shall be paid to the FOUNDATION as detailed below: €2,000 to be paid by Administrative Management of the present contract according to the established in the STUDY BUDGET (APPENDIX SCHEDULE 1); The remainder of the CLINICAL TRIAL budget shall be paid, at least each semester, as detailed in the table of cost per visit and recruited patient included as APPENDIX 1 SCHEDULE 1, until the total cost of the budget is fully paid. The SPONSOR and the PRINCIPAL INVESTIGATOR shall report to the FOUNDATION trimestrally; FOUNDATIONtrimestrally. These instalments shall be considered as partial payments, subject to the settlement of the final total expenses of the CLINICAL theCLINICAL TRIAL. The final contribution of the SPONSOR for the implementation of the CLINICAL TRIAL shall be determined by the activities actually performed while conducting the CLINICAL TRIAL (“Finalcost”). Final cost shall be estimated as follows: Within a maximum of three (3) months from completion of the TRIAL at the HOSPITAL, the SPONSOR/CRO and the PRINCIPALINVESTIGATOR shall report in writing to the FOUNDATION the total number of (1) recruited and evaluated subjects, (2) actual number of visits, (3) resulting incidents, as well as (4) any tests, analyses, examinations, consultations, consultations or hospital stays of special nature that might have occurred, whether or not included in the Financial Schedule (APPENDIX SCHEDULE 1); As soon as possible after the information of the previous point has been reported, the FOUNDATION shall calculate and notify the SPONSOR/CROof the final payment of the CLINICAL TRIAL, as well as the outstanding sums, if any, which shall be paid within one (1) month without further requirement. This settlement of the final payment shall be regarded to all effects as due compliance by the SPONSOR of his financial obligations. All payments shall be made upon the presentation of an invoice; the corresponding VAT shall be included as per current legislation at the time of payment, inthe name of theSPONSOR the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details). ENTITY IN CHARGE OF FINANCIAL ASPECTS (Invoicing Details) NAME VAT NUMBER/ TAX ID NUMBER REGISTERED ADDRESSADDRESS All payments to the Foundation shall be by bank transfer (with bank fees being paid by the payer) to: Beneficiary:La Paz University Hospital Foundation for Biomedical Research CIF/VAT Number/ TAX ID Number: G 00000000 Banking Entity: La Caixa, C/ Hermanos Xxxxxx Xxxxxxxx 18 (Madrid) Account Number:2100 4065 13 2200092143 IBAN: XX00 0000 0000 0000 0000 2143 SWIFT: CAIXE SBB Payments by the SPONSOR/CRO to the FOUNDATION shall be in full satisfaction by the former of its obligations, it being the FOUNDATION’s responsibility to pay the sums, if any, due to the researchers and/or the subjects of the trial.

Euros. €) per subject to be evaluated, as established by the Financial Schedule attached as SCHEDULE 1 to this Agreement, ,which specifies all economic aspects. This amount does not cover or provide for any obligation or commitment for the HOSPITAL, the FOUNDATION and/or the PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, purchase, use, or agree to the use of any of the SPONSOR’s products. The sum to be paid by the SPONSOR/CRO during the implementation of the CLINICAL TRIAL shall be set according to the specifications of SCHEDULE 1, and shall be paid to the FOUNDATION as detailed below: €2,000 to be paid by Administrative Management of the present contract according to the established in the STUDY BUDGET (APPENDIX SCHEDULE 1); The remainder of the CLINICAL TRIAL budget shall be paid, at least each semester, as detailed in the table of cost per visit and recruited patient included as APPENDIX 1 SCHEDULE 1, until the total cost of the budget is fully paid. The SPONSOR and the PRINCIPAL INVESTIGATOR shall report to the FOUNDATION trimestrally; FOUNDATIONtrimestrally. These instalments shall be considered as partial payments, subject to the settlement of the final total expenses of the CLINICAL theCLINICAL TRIAL. The final contribution of the SPONSOR for the implementation of the CLINICAL TRIAL shall be determined by the activities actually performed while conducting the CLINICAL TRIAL (“Finalcost”). Final cost shall be estimated as follows: Within a maximum of three (3) months from completion of the TRIAL at the HOSPITAL, the SPONSOR/CRO and the PRINCIPALINVESTIGATOR shall report in writing to the FOUNDATION the total number of (1) recruited and evaluated subjects, (2) actual number of visits, (3) resulting incidents, as well as (4) any tests, analyses, examinations, consultations, consultations or hospital stays of special nature that might have occurred, whether or not included in the Financial Schedule (APPENDIX SCHEDULE 1); As soon as possible after the information of the previous point has been reported, the FOUNDATION shall calculate and notify the SPONSOR/CROof the final payment of the CLINICAL TRIAL, as well as the outstanding sums, if any, which shall be paid within one (1) month without further requirement. This settlement of the final payment shall be regarded to all effects as due compliance by the SPONSOR of his financial obligations. All payments shall be made upon the presentation of an invoice; the corresponding VAT shall be included as per current legislation at the time of payment, inthe name of theSPONSOR the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details). ENTITY IN CHARGE OF FINANCIAL ASPECTS (Invoicing Details) NAME VAT NUMBER/ TAX ID NUMBER REGISTERED ADDRESSADDRESS All payments to the Foundation shall be by bank transfer (with bank fees being paid by the payer) to: Beneficiary:La Paz University Hospital Foundation for Biomedical Research CIF/VAT Number/ TAX ID Number: G 00000000 Banking Entity: La Caixa, C/ Xxxxxxxx Xxxxxx Xxxxxxxx 18 (Madrid) Account Number:2100 4065 13 2200092143 IBAN: XX00 0000 0000 0000 0000 2143 SWIFT: CAIXE SBB Payments by the SPONSOR/CRO to the FOUNDATION shall be in full satisfaction by the former of its obligations, it being the FOUNDATION’s responsibility to pay the sums, if any, due to the researchers and/or the subjects of the trial.